Research Analysts Offer Predictions for AUPH FY2026 Earnings

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) – Stock analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Aurinia Pharmaceuticals in a research note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst O. Brayer anticipates that the biotechnology company will post earnings of $0.64 per share for the year. The consensus estimate for Aurinia Pharmaceuticals’ current full-year earnings is $0.11 per share.

Separately, Wall Street Zen raised Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 27th.

Aurinia Pharmaceuticals Stock Down 0.7%

Shares of NASDAQ:AUPH opened at $8.13 on Tuesday. The company has a market capitalization of $1.10 billion, a PE ratio of -54.13 and a beta of 1.15. Aurinia Pharmaceuticals has a 52 week low of $5.15 and a 52 week high of $10.67. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60. The company’s fifty day moving average is $7.95 and its 200-day moving average is $8.25.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last issued its earnings results on Monday, May 12th. The biotechnology company reported $0.16 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.08. Aurinia Pharmaceuticals had a negative net margin of 10.23% and a negative return on equity of 4.41%. The business had revenue of $62.47 million for the quarter, compared to analyst estimates of $61.06 million.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Several institutional investors have recently modified their holdings of the stock. Blue Trust Inc. grew its holdings in Aurinia Pharmaceuticals by 3,041.4% during the fourth quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 6,174 shares during the period. Atria Wealth Solutions Inc. acquired a new position in shares of Aurinia Pharmaceuticals in the 4th quarter valued at $135,000. Union Bancaire Privee UBP SA bought a new stake in shares of Aurinia Pharmaceuticals in the 4th quarter valued at $108,000. IFP Advisors Inc increased its position in shares of Aurinia Pharmaceuticals by 31.0% in the 4th quarter. IFP Advisors Inc now owns 271,132 shares of the biotechnology company’s stock valued at $2,435,000 after buying an additional 64,107 shares in the last quarter. Finally, US Bancorp DE raised its stake in Aurinia Pharmaceuticals by 61.9% during the 4th quarter. US Bancorp DE now owns 19,366 shares of the biotechnology company’s stock worth $174,000 after buying an additional 7,406 shares during the period. 36.83% of the stock is currently owned by institutional investors and hedge funds.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.